Xenova Group plc - Scheme of Arrangement Confirmed by Court
August 30, 2005 10:21 ET
|
Xenova Group PLC
SLOUGH, U.K., Aug. 30, 2005 (PRIMEZONE) -- Xenova Group plc ("Xenova") (Nasdaq:XNVA)(LSE:XEN) is pleased to announce that the scheme of arrangement and the reduction of capital comprised within the...
Xenova Group Plc -- Result of Court Meeting and EGM
August 08, 2005 12:23 ET
|
Xenova Group PLC
SLOUGH, U.K., Aug. 8, 2005 (PRIMEZONE) -- Xenova Group Plc ("Xenova") (Nasdaq:XNVA) (LSE:XEN) is pleased to announce that, at a Court Meeting and an Extraordinary General Meeting ("EGM") of its...
Offer for Xenova Group plc
June 24, 2005 02:49 ET
|
Xenova Group PLC
SLOUGH, U.K., June 24, 2005 (PRIMEZONE) -- Xenova Group plc:
Summary
The Directors of Xenova and the Board of Celtic Pharma announce that they have reached agreement on the terms of a recommended...
Xenova Group PLC First Quarter Results, 2005
May 23, 2005 02:47 ET
|
Xenova Group PLC
SLOUGH, U.K., May 23, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced its results for the quarter ended 31 March 2005.
Year to Date Highlights
-- TransMID(TM):...
Xenova Grants Licence to PharmaEngine
April 13, 2005 02:12 ET
|
Xenova Group PLC
SLOUGH, U.K., April 13, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced that it has entered into a licensing agreement for its lead product candidate, TransMID(TM), with...
Xenova Group PLC -- Preliminary Results for the Year Ended 31 December 2004
March 03, 2005 02:33 ET
|
Xenova Group PLC
SLOUGH, U.K., March 3, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced its results for the year ended 31 December 2004.
Announced Today
-- TA-NIC preliminary 12...
Xenova Group plc: Anti-Smoking Vaccine TA-NIC Preliminary 12 Month Clinical Trial Results
March 03, 2005 02:16 ET
|
Xenova Group PLC
SLOUGH, U.K., March 3, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced preliminary 12 month findings from the second Phase I trial of TA-NIC, the Company's therapeutic...
Xenova Group plc -- TransMID Obtains Orphan Drug Designation in Japan
February 14, 2005 02:11 ET
|
Xenova Group PLC
SLOUGH, U.K., Feb. 14, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced that, Sosei Co. Ltd. (Sosei) (4565, Tokyo Stock Exchange MOTHERS Index), its licensee for the...
Xenova Licenses DISC-HSV and DISC-GM-CSF Vector Technologies to Oxxon
January 13, 2005 02:21 ET
|
Xenova Group PLC
SLOUGH, U.K., Jan. 13, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced it has signed an exclusive licensing agreement with Oxxon Therapeutics Ltd (Oxxon) potentially...
Xenova Licenses TA-CIN to Cancer Research Technology
January 10, 2005 02:21 ET
|
Xenova Group PLC
SLOUGH, U.K., Jan. 10, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced that it has entered into a licensing agreement with Cancer Research Technology Limited (CRT) in...